• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

硫酸乙酰肝素模拟物在癌症治疗中的应用:定义结构决定因素和目标相关性的挑战,以实现最佳活性。

Heparan Sulfate Mimetics in Cancer Therapy: The Challenge to Define Structural Determinants and the Relevance of Targets for Optimal Activity.

机构信息

Molecular Pharmacology Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.

出版信息

Molecules. 2018 Nov 8;23(11):2915. doi: 10.3390/molecules23112915.

DOI:10.3390/molecules23112915
PMID:30413079
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6278363/
Abstract

Beyond anticoagulation, the therapeutic potential of heparin derivatives and heparan sulfate (HS) mimetics (functionally defined HS mimetics) in oncology is related to their ability to bind and modulate the function of a vast array of HS-binding proteins with pivotal roles in cancer growth and progression. The definition of structural/functional determinants and the introduction of chemical modifications enabled heparin derivatives to be identified with greatly reduced or absent anticoagulant activity, but conserved/enhanced anticancer activity. These studies paved the way for the disclosure of structural requirements for the inhibitory effects of HS mimetics on heparanase, selectins, and growth factor receptor signaling, as well as for the limitation of side effects. Actually, HS mimetics affect the tumor biological behavior via a multi-target mechanism of action based on their effects on tumor cells and various components of the tumor microenvironment. Emerging evidence indicates that immunomodulation can participate in the antitumor activity of these agents. Significant ability to enhance the antitumor effects of combination treatments with standard therapies was shown in several tumor models. While the first HS mimetics are undergoing early clinical evaluation, an improved understanding of the molecular contexts favoring the antitumor action in certain malignancies or subgroups is needed to fully exploit their potential.

摘要

除了抗凝作用外,肝素衍生物和硫酸乙酰肝素(HS)类似物(功能定义的 HS 类似物)在肿瘤学中的治疗潜力与其结合和调节 HS 结合蛋白功能的能力有关,这些 HS 结合蛋白在癌症生长和进展中具有关键作用。结构/功能决定因素的定义和化学修饰的引入使肝素衍生物能够具有大大降低或缺失的抗凝活性,但保留/增强的抗癌活性。这些研究为揭示 HS 类似物对肝素酶、选择素和生长因子受体信号的抑制作用的结构要求以及限制副作用铺平了道路。实际上,HS 类似物通过基于它们对肿瘤细胞和肿瘤微环境各种成分的影响的多靶点作用机制来影响肿瘤的生物学行为。有证据表明,免疫调节可以参与这些药物的抗肿瘤活性。在几种肿瘤模型中,这些药物与标准治疗联合使用时显著增强了抗肿瘤效果。虽然第一批 HS 类似物正在进行早期临床评估,但需要更好地了解在某些恶性肿瘤或亚组中有利于抗肿瘤作用的分子环境,以充分发挥其潜力。

相似文献

1
Heparan Sulfate Mimetics in Cancer Therapy: The Challenge to Define Structural Determinants and the Relevance of Targets for Optimal Activity.硫酸乙酰肝素模拟物在癌症治疗中的应用:定义结构决定因素和目标相关性的挑战,以实现最佳活性。
Molecules. 2018 Nov 8;23(11):2915. doi: 10.3390/molecules23112915.
2
The Challenge of Modulating Heparan Sulfate Turnover by Multitarget Heparin Derivatives.多靶点肝素衍生物调控硫酸乙酰肝素代谢的挑战。
Molecules. 2020 Jan 17;25(2):390. doi: 10.3390/molecules25020390.
3
Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer.肝素衍生的硫酸乙酰肝素模拟物调节炎症和癌症中的硫酸乙酰肝素蛋白相互作用。
Matrix Biol. 2010 Jul;29(6):442-52. doi: 10.1016/j.matbio.2010.04.003. Epub 2010 Apr 21.
4
Use of sulfated linked cyclitols as heparan sulfate mimetics to probe the heparin/heparan sulfate binding specificity of proteins.使用硫酸化连接环醇作为硫酸乙酰肝素模拟物来探究蛋白质的肝素/硫酸乙酰肝素结合特异性。
J Biol Chem. 2005 Mar 11;280(10):8842-9. doi: 10.1074/jbc.M410769200. Epub 2005 Jan 4.
5
Receptor tyrosine kinases and heparan sulfate proteoglycans: Interplay providing anticancer targeting strategies and new therapeutic opportunities.受体酪氨酸激酶和硫酸乙酰肝素蛋白聚糖:相互作用提供抗癌靶向策略和新的治疗机会。
Biochem Pharmacol. 2020 Aug;178:114084. doi: 10.1016/j.bcp.2020.114084. Epub 2020 Jun 9.
6
PI-88 and novel heparan sulfate mimetics inhibit angiogenesis.PI-88及新型硫酸乙酰肝素模拟物可抑制血管生成。
Semin Thromb Hemost. 2007 Jul;33(5):557-68. doi: 10.1055/s-2007-982088.
7
Heparan sulfate signaling in cancer.癌症中的硫酸乙酰肝素信号传导
Trends Biochem Sci. 2014 Jun;39(6):277-88. doi: 10.1016/j.tibs.2014.03.001. Epub 2014 Apr 19.
8
Molecular Aspects of Heparanase Interaction with Heparan Sulfate, Heparin and Glycol Split Heparin.肝素酶与硫酸乙酰肝素、肝素和糖分解肝素相互作用的分子方面。
Adv Exp Med Biol. 2020;1221:169-188. doi: 10.1007/978-3-030-34521-1_6.
9
Dendrimer Heparan Sulfate Glycomimetics: Potent Heparanase Inhibitors for Anticancer Therapy.树状肝素硫酸糖仿生物:用于癌症治疗的强效肝素酶抑制剂。
ACS Chem Biol. 2018 Dec 21;13(12):3236-3242. doi: 10.1021/acschembio.8b00909. Epub 2018 Nov 29.
10
PI-88 and Related Heparan Sulfate Mimetics.PI-88 及相关硫酸乙酰肝素类似物。
Adv Exp Med Biol. 2020;1221:473-491. doi: 10.1007/978-3-030-34521-1_19.

引用本文的文献

1
Expanding the Role of Heparin Derivatives in Oncology: From Anticoagulation to Antitumor Activity.扩大肝素衍生物在肿瘤学中的作用:从抗凝到抗肿瘤活性。
Pharmaceuticals (Basel). 2025 Mar 12;18(3):396. doi: 10.3390/ph18030396.
2
Sulfatase 2 inhibition sensitizes triple-negative breast cancer cells to paclitaxel through augmentation of extracellular ATP.硫酸酯酶2抑制通过增加细胞外ATP使三阴性乳腺癌细胞对紫杉醇敏感。
Cancer Biol Ther. 2025 Dec;26(1):2483989. doi: 10.1080/15384047.2025.2483989. Epub 2025 Mar 26.
3
Extracellular Matrix as a Target in Melanoma Therapy: From Hypothesis to Clinical Trials.

本文引用的文献

1
Heparan Sulfate and Heparan Sulfate Proteoglycans in Cancer Initiation and Progression.硫酸乙酰肝素及硫酸乙酰肝素蛋白聚糖在癌症起始与进展中的作用
Front Endocrinol (Lausanne). 2018 Aug 24;9:483. doi: 10.3389/fendo.2018.00483. eCollection 2018.
2
Cancer and Thrombosis-New Insights.癌症与血栓形成——新见解
Rambam Maimonides Med J. 2018 Sep 2;9(4):1-7. doi: 10.5041/RMMJ.10349.
3
The heparanase inhibitor PG545 is a potent anti-lymphoma drug: Mode of action.硫酸乙酰肝素酶抑制剂 PG545 是一种强效的抗淋巴瘤药物:作用机制。
细胞外基质作为黑色素瘤治疗的靶点:从假设到临床试验。
Cells. 2024 Nov 19;13(22):1917. doi: 10.3390/cells13221917.
4
The role of heparan sulfate in enhancing the chemotherapeutic response in triple-negative breast cancer.硫酸乙酰肝素在增强三阴性乳腺癌化疗反应中的作用。
Breast Cancer Res. 2024 Nov 6;26(1):153. doi: 10.1186/s13058-024-01906-6.
5
A charged tail on anti-α-Synuclein antibodies does not enhance their affinity to α-Synuclein fibrils.带电荷的抗α-突触核蛋白抗体的尾部不会增强其与α-突触核蛋白纤维的亲和力。
PLoS One. 2024 Aug 29;19(8):e0308521. doi: 10.1371/journal.pone.0308521. eCollection 2024.
6
A tumor-associated heparan sulfate-related glycosaminoglycan promotes the generation of functional regulatory T cells.一种与肿瘤相关的肝素硫酸相关糖胺聚糖促进功能性调节性 T 细胞的生成。
Cell Mol Immunol. 2023 Dec;20(12):1499-1512. doi: 10.1038/s41423-023-01096-9. Epub 2023 Nov 22.
7
The Glycosaminoglycan Side Chains and Modular Core Proteins of Heparan Sulphate Proteoglycans and the Varied Ways They Provide Tissue Protection by Regulating Physiological Processes and Cellular Behaviour.糖胺聚糖侧链和硫酸乙酰肝素蛋白聚糖的模块化核心蛋白,以及它们通过调节生理过程和细胞行为提供组织保护的多种方式。
Int J Mol Sci. 2023 Sep 14;24(18):14101. doi: 10.3390/ijms241814101.
8
VSIG4 interaction with heparan sulfates inhibits VSIG4-complement binding.VSIG4 与硫酸乙酰肝素的相互作用抑制了 VSIG4-补体的结合。
Glycobiology. 2023 Aug 14;33(7):591-604. doi: 10.1093/glycob/cwad050.
9
Discovery and development of small-molecule heparanase inhibitors.小分子乙酰肝素酶抑制剂的发现与研制。
Bioorg Med Chem. 2023 Jul 15;90:117335. doi: 10.1016/j.bmc.2023.117335. Epub 2023 May 19.
10
Heparan Sulfate Proteoglycans in Tauopathy.硫酸乙酰肝素蛋白聚糖在 Tau 病中的作用。
Biomolecules. 2022 Nov 30;12(12):1792. doi: 10.3390/biom12121792.
Matrix Biol. 2019 Apr;77:58-72. doi: 10.1016/j.matbio.2018.08.005. Epub 2018 Aug 7.
4
Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors.皮沙他莫的免疫调节活性:新兴的非临床和临床数据,及其与 PD-1 抑制剂联合应用的潜在效用。
J Immunother Cancer. 2018 Jun 14;6(1):54. doi: 10.1186/s40425-018-0363-5.
5
Patient derived xenografts (PDX) predict an effective heparanase-based therapy for lung cancer.患者来源的异种移植(PDX)预测基于乙酰肝素酶的肺癌治疗有效。
Oncotarget. 2018 Apr 10;9(27):19294-19306. doi: 10.18632/oncotarget.25022.
6
Phase I study of the heparanase inhibitor roneparstat: an innovative approach for ultiple myeloma therapy.硫酸乙酰肝素酶抑制剂罗内帕司他的I期研究:一种用于多发性骨髓瘤治疗的创新方法。
Haematologica. 2018 Oct;103(10):e469-e472. doi: 10.3324/haematol.2017.182865. Epub 2018 Apr 26.
7
2-O, 3-O desulfated heparin mitigates murine chemotherapy- and radiation-induced thrombocytopenia.2-O, 3-O 去硫酸化肝素减轻小鼠化疗和放疗诱导的血小板减少症。
Blood Adv. 2018 Apr 10;2(7):754-761. doi: 10.1182/bloodadvances.2017013672.
8
Involvement of Heparanase in the Pathogenesis of Mesothelioma: Basic Aspects and Clinical Applications.肝素酶在间皮瘤发病机制中的作用:基础方面和临床应用。
J Natl Cancer Inst. 2018 Oct 1;110(10):1102-1114. doi: 10.1093/jnci/djy032.
9
A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours.一项新型免疫调节剂 PG545(pixatimod)在晚期实体瘤患者中的 I 期研究。
Br J Cancer. 2018 Apr;118(8):1035-1041. doi: 10.1038/s41416-018-0006-0. Epub 2018 Mar 13.
10
Pleiotropic effects of heparins: does anticoagulant treatment increase survival in cancer patients?肝素的多效性作用:抗凝治疗是否能提高癌症患者的生存率?
Clin Transl Oncol. 2018 Sep;20(9):1097-1108. doi: 10.1007/s12094-018-1835-2. Epub 2018 Feb 22.